Meredith Irwin, MD
The Hospital for Sick Children
Associate Chair (Research)
University of Toronto
Departments of Paediatrics, Medical Biophysics and Laboratory Medicine & Pathobiology
Phone: 416-813-7654 ext. 302912
Dr. Irwin received her Bachelors of Science at the Massachusetts Institute of Technology in 1988. She then received her Medical Degree in 1992 from Harvard Medical School. She completed her Paediatric Residency at the Boston Children’s Hospital in 1995, and continued subspecialty training (fellowship) in Paediatric Hematology-Oncology at Boston Children’s Hospital and Dana-Farber Cancer Institute at Harvard Medical School in Boston, Massachusetts. In 1998 Dr. Irwin was appointed as an Instructor of Paediatrics at Harvard Medical School and was on staff at Boston Children’s Hospital and Dana-Farber Cancer Institute as a Clinician-Scientist, spending approximately 80 per cent of her time performing basic science research, and 20 per cent as a staff physician in the inpatient and outpatient oncology and bone marrow transplantation wards.
In 1997 Dr. Irwin began a research fellowship in the laboratory of Dr. William Kaelin, a Howard Hughes Medical Investigator at the Dana-Farber Cancer Institute. Her research was supported by grants from the American Cancer Society and the National Institute of Health. During her research fellowship, Dr. Irwin studied the role of the newly identified p53-related genes, p73 and p63, in cancer. p53 is the most commonly altered gene in human cancer.
Dr. Irwin joined the Division of Haematology-Oncology at SickKids in April 2002 as a Clinician-Scientist. She has set up a research laboratory in the Cell Biology Research Program. Her laboratory studies the role of the p53-family of genes in tumour cell death pathways, and specifically how treatments, such as chemotherapy, use these genes to kill tumour cells.
Since joining SickKids Dr. Irwin has been awarded funding from CIHR, NCIC and as well, has been awarded a Canada Research Chair (Tier II).
Areas of Specialty:
Neuroblastoma, Solid Tumours.
Clinical Care Activities:
My clinical activities are focused on the care of children with solid tumours, and mainly neuroblastoma. I am the SickKids Primary investigator for several Children's Oncology Group (COG) Neuroblastoma clinical trials and am a member of the COG Neuroblastoma Biology committee. I also run a SickKids neuroblastoma tumour banking protocol.
- Role of p53 family genes (p73 and p63) in cancer and chemotherapy sensitivity
- Identification of p73 and p63 interacting proteins and post-translational modifications
- Role of p53 family proteins in Neuroblastoma
- Novel therapies for metastatic Neuroblatoma
For full list of publications, please see PubMed.